TIDMNSCI
NetScientific PLC
15 February 2017
NetScientific plc
("NetScientific" or the "Company")
Vortex Biosciences' Chief Scientific Officer, Elodie Sollier
Awarded 2017 SLAS Innovation Award
London, UK - 15 February 2017 - NetScientific plc
("NetScientific", AIM:NSCI), the transatlantic healthcare IP
commercialisation Group, announces that the Chief Scientific
Officer of its portfolio company, Vortex Biosciences, Elodie
Sollier-Christen, has been awarded a 2017 Society for Laboratory
Automation and Screening (SLAS) Innovation Award.
Elodie's presentation to the judges: "Vortex Technology for fast
and label-free isolation of circulating tumour cells from blood
samples", where she discussed a breakthrough by Vortex in the
isolation of circulating tumour cells from blood samples, is now
available to view on the SLAS website (www.slas.org).
The annual SLAS Innovation Award recognizes extraordinary
achievement in innovative life sciences discovery and technology.
All those selected to deliver podium presentations at the annual
SLAS conference are eligible to be considered for this award, which
comes with a $10,000 prize.
Commenting on the news, François R. Martelet, Chief Executive
Officer of NetScientific, said: "We wish to extend our warm
congratulations to Elodie on her receipt of this prestigious award.
We view this prize as a recognition of her extraordinary work on
the cutting edge technology utilised by Vortex on the design of the
VTX-1 Liquid Biopsy System. We believe that this technology has
great potential to significantly impact laboratory automation and
screening and we are delighted to see it receive due
recognition."
The full text of the announcement is below:
CSO of Vortex Biosciences Dr. Elodie Sollier-Christen Awarded
With 2017 SLAS Innovation Award
Dr. Elodie Sollier-Christen's Presentation on the Development of
the VTX-1 Liquid Biopsy System Recognized for Innovation and Impact
to Research
MENLO PARK, CA, 14 February 2017 - Vortex Biosciences, provider
of circulating tumor cell (CTC) capture systems, congratulates
Chief Scientific Officer (CSO) Dr. Elodie Sollier-Christen for
receiving the Innovation Award at SLAS 2017, the annual conference
and exhibition of the Society for Laboratory Automation and
Screening (SLAS), held Feb. 4-8 in Washington D.C. Her
presentation, now available for viewing on the SLAS website is
titled "Vortex Technology for fast and label-free isolation of
circulating tumor cells from blood samples" and described the
development of the new VTX-1 Liquid Biopsy System.
The annual SLAS Innovation Award recognizes extraordinary
achievement in innovative life sciences discovery and technology.
After receiving nominations from 83 SLAS 2017 podium presenters,
the SLAS Innovation Award panel of judges invited 21 presenters to
submit extended abstracts for further consideration. Of these 21
extended abstracts, 9 were identified as finalists and were invited
to deliver podium presentations for evaluation at the SLAS 2017
conference. Finalists were selected after the judges determined
that these scientists offered especially insightful studies to
develop new technology for the laboratory; a new application of
technology to laboratory automation or screening; or a use of
technology to solve a unique problem. The complete judging criteria
can be seen on the Innovation Award page of the SLAS 2017
website.
"I am humbled by the honor a great organization like SLAS has
given me," said Elodie Sollier-Christen, Chief Scientific Officer
of Vortex Biosciences. "I am so proud to be part of the Vortex
team, translating innovative laboratory science into a great
product that will have a real impact on our understanding of cancer
biology and ultimately improve outcomes for cancer patients."
"The VTX-1 product is truly the next step in CTC isolation
technologies, and will have a huge impact on both cancer research
and diagnostics," said Gene Walther, Chief Executive Officer of
Vortex Biosciences. "We are proud to see great scientists like Dr.
Sollier-Christen be recognized for the cutting edge work she and
her team are doing."
CTCs are relatively scarce, with concentrations as low as 1-10
CTCs/mL of whole blood, against a background of millions of white
blood cells and billions of red blood cells. Based on innovations
in Dr. Dino Di Carlo's lab at the University of California, Los
Angeles (UCLA), the fully automated, easy to use VTX-1 Liquid
Biopsy System from Vortex represents the next step in CTC
isolation. Inside the VTX-1 chip, unlabeled CTCs in whole blood are
selectively trapped in microscale vortices while smaller red and
white blood cells pass through. The CTCs are then released and
collected into a variety of containers for downstream analysis.
With a cancer cell recovery of 65-75%, best in class CTC purity,
CTCs collected unbiased by their molecular characteristics,
unaltered by the process, and ready for downstream analysis, the
VTX-1 offers the best CTC samples available today. Dr.
Sollier-Christen's winning presentation went through the
development process from an early, exciting technology to a refined
commercial product.
About Vortex Biosciences
Vortex Biosciences is a cancer research and diagnostics company
that integrates cancer biology, microfluidic engineering and
informatics to develop tools for isolating and characterizing
circulating tumor cells. The Vortex VTX-1 instrument harvests
intact circulating tumor cells from whole blood samples for use in
downstream research and clinical applications such as patient
stratification in clinical trials, monitoring disease progression
and drug treatment effectiveness. With a mission to enable
noninvasive diagnosis of cancer and real-time monitoring throughout
a patient's treatment, Vortex is at the forefront of accelerating
cancer research and improving patient outcomes. Vortex is a core
subsidiary of NetScientific plc, a transatlantic healthcare
technology group with an investment strategy focused on sourcing,
funding and commercializing technologies that significantly improve
the health and well-being of people with chronic diseases. For more
information, visit www.vortexbiosciences.com.
For more information, please contact:
NetScientific Tel: +44 (0)20 3514 1800
François R. Martelet,
M.D., CEO
Ian Postlethwaite,
CFO
Consilium Strategic
Communications Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / netscientific@consilium-comms.com
Chris Gardner /
Jessica Hodgson / Chris
Welsh /
Laura Thornton
About NetScientific Plc
NetScientific is a transatlantic healthcare technology group
with an investment strategy focused on sourcing, funding and
commercialising technologies that significantly improve the health
and well-being of people with chronic diseases.
For more information, please visit the website at
www.netscientific.net
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAKMGMZNDNGNZM
(END) Dow Jones Newswires
February 15, 2017 02:00 ET (07:00 GMT)
Netscientific (LSE:NSCI)
Historical Stock Chart
From Apr 2024 to May 2024
Netscientific (LSE:NSCI)
Historical Stock Chart
From May 2023 to May 2024